Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Objective</h3><p>: To evaluate the efficacy and safety of Hua Shi Bai Du Granule (Q-14) plus standard care compared with standard care alone in adults with coronavirus disease (COVID-19).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Study Design</h3><p>: A single-center, open-label, randomized controlled trial.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Setting</h3><p>: Wuhan Jinyintan Hospital, Wuhan, China, February 27 to March 27, 2020.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Participants</h3><p>: A total of 204 patients with laboratory-confirmed COVID-19 were randomized into the treatment group and control group, consisting of 102 patients in each group.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Interventions</h3><p>: In the treatment group, Q-14 was administered at 10 g (granules) twice daily for 14 days, plus standard care. In the control group, patients were provided standard care alone for 14 days.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Main Outcome Measure</h3><p>: The primary outcome was the conversion time for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral assay. Adverse events were analyzed in the safety population.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>: Among the 204 patients, 195 were analyzed according to the intention-to-treat principle. A totalof 149 patients (71 vs. 78 in the treatment and control groups, respectively) tested negative via the SARS-CoV-2 viral assay. There was no statistical significance in the conversion time between the treatment group and control group (full analysis set: median (interquartile range): 10.00 (9.00-11.00) vs. 10.00 (9.00-11.00); mean rank: 67.92 vs. 81.44; P=0.051.). The recovery time for fever was shorter in the treatment group than in the control group. The disappearance rate of symptomslike cough, fatigue, and chest discomfort was significantly higher in the treatment group. In chest computed tomography (CT) examinations, the overall evaluation of chest CT examination after treatment compared with baseline showed that more patients showed improvement in the treatment group. There were no significant differences in the other outcomes.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3><p>: The combination of Q-14 and standard care for COVID-19 was useful for the improvement of symptoms (such as fever, cough, fatigue, and chest discomfort), but did not result in a significantly higher probability of negative conversion in the SARS-CoV-2 viral assay. No serious adverse events were observed.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Trial Registration</h3><p>: ChiCTR2000030288</p>

[Clinical Observation on Treatment of SARS with Combination of Chaihu Droplet Pill and Huoxiang Zhengqi Droplet Pill].

Observation of Therapeutic Effects of Dachengqi Decoction Combined with Recruitment Maneuver on Patients with Extra-pulmonary Acute Respiratory Distress Syndrome

Symptom Combinations Associated with Outcome and Therapeutic Effects in a Cohort of Cases with SARS.

Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: A randomized controlled trial

[The Clinical Characteristics and Outcome of 45 Early Stage Patients with SARS].

Application of ultrashort wave diathermy in treatment of severe acute respiratory syndrome

Clinical Analysis of 120 Cases of Patients with Severe Acute Respiratory Syndrome

[Clinical Study on Treatment of Severe Acute Respiratory Syndrome by Integrative Chinese and Western Medicine].

Effects of Different Therapeutic Schedules on Patients with COVID-19: A Prospective Case–Control Study in China

Chinese Herbal Medicine for Severe Acute Respiratory Syndrome: a Systematic Review and Meta-Analysis.

Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China

Effect of integrative Chinese and western medicine on acute exacerbation of chronic obstructive pulmonary disease combined with respiratory failure

Clinical Features and Therapy of SARS Patients with Diarrhea

[Discussion about treatment of severe acute respiratory syndrome based on syndrome differentiation]

Hydroxychloroquine treatment in COVID‐19: A descriptive observational analysis of 30 cases from a single center in Wuhan, China

Add-on effect of Chinese herbal medicine in the treatment of mild to moderate COVID-19: A systematic review and meta-analysis

Effect and safety of Chinese herbal medicine granules in patients with severe coronavirus disease 2019 in Wuhan, China: a retrospective, single-center study with propensity score matching

Effect observation of cefotaxime sodium combined with xiaochaihu decoction in the treatment of lower respiratory tract infection

Clinical investigation of outbreak of nosocomial severe acute respiratory syndrome]

Effect of Integrated Traditional Chinese Medicine and Western Medicine on the Treatment of Severe Acute Respiratory Syndrome: A Meta-Analysis

Combination of Hua Shi Bai Du granule (Q-14) and standard care in the treatment of patients with coronavirus disease 2019 (COVID-19): A single-center, open-label, randomized controlled trial